In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.

Christian Bolenz,Christel Weiss,M. Wenzel,Ute Gabriel,Annette Steidler,Andreas Becker,Edwin Herrmann,Lutz Trojan,Maurice Stephan Michel

In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.

2009

Christian Bolenz
Christel Weiss
M. Wenzel
Ute Gabriel
Annette Steidler
Andreas Becker
Edwin Herrmann
Lutz Trojan
Maurice Stephan Michel

Purpose To evaluate intravesical paclitaxel monotherapy and combined treatment with antiapoptotic bcl-xL antisense oligodeoxynucleotides (AS-ODNs) on urothelial carcinoma (UC).

Keywords:

Cancer
Urinary bladder
Carcinoma
Bcl-xL
Sense (molecular biology)
Immunology
In vivo
Pathology
Transitional cell carcinoma
Paclitaxel
Medicine
urothelial carcinoma
Hematology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations